Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451383 · ClinicalTrials.gov registry record
Older Breast Cancer Patients: Risk for Cognitive Decline
A clinical trial of Cognitive Decline and Cancer, Breast, sponsored by Georgetown University.
- Recruiting
- Registry status
- 1,700
- Enrollment target
- 1
- Study location
NCT03451383: Recruiting study of Cognitive Decline and Cancer, Breast, sponsored by Georgetown University.
NCT03451383 is a study of Cognitive Decline and Cancer, Breast that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 1,700 participants, above the 1,122-participant average among 61 other Cognitive Decline trials with a reported enrollment target (52% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451383, a study of Cognitive Decline and Cancer, Breast, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- 1,700 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes. This study is being done nationally, with recruiting sites at Georgetown University, Montgomery General Hospital, Virginia Cancer Specialists, Washington Hospital Center, Reston Breast Care Specialists, Memorial Sloan-Kettering, Moffitt Cancer Center, City of Hope National Medical Center, Hackensack University Medical Center, Indiana University and University of California, Los Angeles.
Primary Outcome
Using neuropsychological tests: NAB Digits Forward and Backward, Trailmaking A and B, Digit Symbol Subtest-Wechsler Adult, The Timed Instrumental Activities of Daily Living, Controlled Oral Word Association Test, NAB Driving Scenes and NAB Figure Drawing. These measures are aggregated to arrive at one reported value. The individual tests are first selected via factor analysis, then the selected raw scores are standardized to baseline controls by age and education group. The final domain score is
Conditions Studied
Study Locations (1)
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2010-08-01 |
| Est. Completion | 2025-04-30 |
What NCT03451383 shows while recruiting
NCT03451383 is an observational study that tracks outcomes without assigning an intervention. Its 1,700 participants enrollment target places it among the larger protocols in the corpus, above the 1,122-participant average among 61 other Cognitive Decline trials with a reported enrollment target (52% higher).
The record links to 3 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 0 interventions.
NCT03451383 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03451383 about?
NCT03451383 is a clinical study titled "Older Breast Cancer Patients: Risk for Cognitive Decline". The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physi...
What is the current status of trial NCT03451383?
This trial is currently recruiting. The enrollment target is 1,700 participants. The study started on 2010-08-01. Estimated completion is 2025-04-30.
What conditions does trial NCT03451383 study?
This clinical trial studies the following conditions: Cognitive Decline, Cancer, Breast, Age-related Cognitive Decline.
Who is sponsoring clinical trial NCT03451383?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03451383 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03451383's enrollment target sits among peer trials
1,700 6th of 61 higher than 56 of 61 other Cognitive Decline trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
-
mPATH for Low-income Older Adults
RECRUITING · NA
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Glucose Variability and Cognition in Prediabetes
RECRUITING
-
MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI